{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:45:27Z","timestamp":1785905127349,"version":"3.56.0"},"reference-count":228,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62171236"],"award-info":[{"award-number":["62171236"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62571264"],"award-info":[{"award-number":["62571264"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bcp.2026.118184","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:17:37Z","timestamp":1782170257000},"page":"118184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Multidimensional regulatory networks of drug resistance in colorectal cancer: from molecular mechanisms to novel therapeutic counterstrategies"],"prefix":"10.1016","volume":"251","author":[{"given":"Jie","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-0010","authenticated-orcid":false,"given":"Tingming","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2026.118184_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.bcp.2026.118184_b0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN","volume":"72","author":"Morgan","year":"2023","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.bcp.2026.118184_b0015","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","article-title":"Metastatic colorectal cancer: mechanisms and emerging therapeutics","volume":"44","author":"Shin","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118184_b0020","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10555-023-10158-3","article-title":"Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments","volume":"43","author":"Abedizadeh","year":"2024","journal-title":"Cancer Metastasis Rev."},{"issue":"9","key":"10.1016\/j.bcp.2026.118184_b0025","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of Multidrug Resistance in Cancer Chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.118184_b0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10585-018-9903-0","article-title":"The challenge of drugresistance in cancer treatment: a current overview","volume":"35","author":"Nikolaou","year":"2018","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.bcp.2026.118184_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100796","article-title":"Anticancer drug resistance: An update and perspective","volume":"59","author":"Nussinov","year":"2021","journal-title":"Drug Resist. Updat."},{"issue":"2 d","key":"10.1016\/j.bcp.2026.118184_b0040","article-title":"Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"6","key":"10.1016\/j.bcp.2026.118184_b0045","doi-asserted-by":"crossref","first-page":"366","DOI":"10.6004\/jnccn.2024.0041","article-title":"NCCN Guidelines\u00ae Insights: Rectal Cancer, Version 3.2024","volume":"22","author":"Benson","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"4","key":"10.1016\/j.bcp.2026.118184_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100184","article-title":"How I treat stage II colon cancer patients","volume":"6","author":"Taieb","year":"2021","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.bcp.2026.118184_b0055","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","article-title":"Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials","volume":"21","author":"Andr\u00e9","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.118184_b0060","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejca.2020.09.037","article-title":"Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review","volume":"141","author":"Bolhuis","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"23","key":"10.1016\/j.bcp.2026.118184_b0065","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118184_b0080","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S1470-2045(16)30269-8","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial","volume":"17","author":"Stintzing","year":"2016","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118184_b0085","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bcp.2026.118184_b0090","first-page":"854","article-title":"Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment","volume":"10","author":"Azwar","year":"2021","journal-title":"Biology (Basel)"},{"issue":"2","key":"10.1016\/j.bcp.2026.118184_b0095","doi-asserted-by":"crossref","first-page":"269","DOI":"10.7150\/ijms.102976","article-title":"PUF60 Promotes Chemoresistance Through Drug Efflux and Reducing Apoptosis in Gastric Cancer","volume":"22","author":"Liu","year":"2025","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.bcp.2026.118184_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117588","article-title":"Formononetin inhibits colorectal cancer via the miR-490-3p\/ABCC2 axis and synergizes with 5-fluorouracil: mechanistic insights and therapeutic implications","volume":"244","author":"Yu","year":"2026","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118184_b0105","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1042\/BST20160038","article-title":"The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30-year collaborative odyssey","volume":"44","author":"Young","year":"2016","journal-title":"Biochem. Soc. Trans."},{"issue":"3","key":"10.1016\/j.bcp.2026.118184_b0110","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1039\/C7MT00334J","article-title":"Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells","volume":"10","author":"Bu\u00df","year":"2018","journal-title":"Metallomics"},{"key":"10.1016\/j.bcp.2026.118184_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113520","article-title":"Organic cation transporter 2 activation enhances sensitivity to oxaliplatin in human pancreatic ductal adenocarcinoma","volume":"153","author":"Chiu","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2026.118184_b0120","article-title":"Efflux ABC transporters in drug disposition and their posttranscriptional gene regulation by microRNAs","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"18","key":"10.1016\/j.bcp.2026.118184_b0125","doi-asserted-by":"crossref","first-page":"9973","DOI":"10.3390\/ijms25189973","article-title":"Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer","volume":"25","author":"Maimaitijiang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.118184_b0130","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3390\/ma13071483","article-title":"Microfluidic-Assisted Preparation of 5-Fluorouracil-Loaded PLGA Nanoparticles as a Potential System for Colorectal Cancer Therapy","volume":"13","author":"Ghasemi Toudeshkchouei","year":"2020","journal-title":"Materials (Basel)"},{"key":"10.1016\/j.bcp.2026.118184_b0135","article-title":"Gemini surfactant-stabilized cubosomes for enhanced topical delivery of 5-fluorouracil in cutaneous squamous cell carcinoma","volume":"11","author":"Raychaudhuri","year":"2026","journal-title":"Int J Pharm X"},{"key":"10.1016\/j.bcp.2026.118184_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116161","article-title":"Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study","volume":"233","author":"Borrego","year":"2026","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bcp.2026.118184_b0145","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jconrel.2021.08.050","article-title":"A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction","volume":"338","author":"Gao","year":"2021","journal-title":"J. Control. Release"},{"issue":"13","key":"10.1016\/j.bcp.2026.118184_b0150","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.3390\/cancers13133130","article-title":"Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer","volume":"13","author":"Tomasini","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"18","key":"10.1016\/j.bcp.2026.118184_b0155","doi-asserted-by":"crossref","first-page":"9537","DOI":"10.1093\/nar\/gky764","article-title":"Base and nucleotide excision repair facilitate resolution of platinum drugs-induced transcription blockage","volume":"46","author":"Slyskova","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"53","key":"10.1016\/j.bcp.2026.118184_b0160","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.18632\/oncotarget.27140","article-title":"Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin","volume":"10","author":"Rao","year":"2019","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41389-023-00458-2","article-title":"USP35 promotes cell proliferation and chemotherapeutic resistance through stabilizing FUCA1 in colorectal cancer","volume":"12","author":"Xiao","year":"2023","journal-title":"Oncogenesis"},{"key":"10.1016\/j.bcp.2026.118184_b0170","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2147\/OTT.S192923","article-title":"Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer","volume":"12","author":"Liu","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13046-020-01811-8","article-title":"Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer","volume":"40","author":"Vitiello","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118184_b0180","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70332","article-title":"Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial","volume":"132","author":"Doroshow","year":"2026","journal-title":"Cancer"},{"issue":"31","key":"10.1016\/j.bcp.2026.118184_b0185","doi-asserted-by":"crossref","first-page":"15469","DOI":"10.1073\/pnas.1904523116","article-title":"BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammals","volume":"116","author":"Srivastava","year":"2019","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.bcp.2026.118184_b0190","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1007\/s11033-019-04826-3","article-title":"Enhancement of chemosensitivity in 5-fluorouracil-resistant colon cancer cells with carcinoembryonic antigen-specific RNA aptamer","volume":"46","author":"Lee","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bcp.2026.118184_b0195","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.924290","article-title":"Autophagy: A Versatile Player in the Progression of Colorectal Cancer and Drug Resistance","volume":"12","author":"Manzoor","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118184_b0200","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.neo.2021.12.003","article-title":"MLH1 mediates cytoprotective nucleophagy to resist 5-Fluorouracil-induced cell death in colorectal carcinoma","volume":"24","author":"Manzoor","year":"2022","journal-title":"Neoplasia"},{"issue":"11","key":"10.1016\/j.bcp.2026.118184_b0205","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1158\/1078-0432.CCR-12-1542","article-title":"Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy","volume":"19","author":"Selvakumaran","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118184_b0210","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.2147\/OTT.S240803","article-title":"Irinotecan Induces Autophagy-Dependent Apoptosis and Positively Regulates ROS-Related JNK- and P38-MAPK Pathways in Gastric Cancer Cells","volume":"13","author":"Zhu","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"11","key":"10.1016\/j.bcp.2026.118184_b0215","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/s41418-018-0082-y","article-title":"Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant\/TL32711","volume":"25","author":"Crawford","year":"2018","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.bcp.2026.118184_b0220","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s43587-025-00811-7","article-title":"A BCL-xL\/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice","volume":"5","author":"Yang","year":"2025","journal-title":"Nat. Aging"},{"key":"10.1016\/j.bcp.2026.118184_b0225","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/1471-2407-10-370","article-title":"Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells","volume":"10","author":"Sasaki","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2026.118184_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107447","article-title":"5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future","volume":"206","author":"Vodenkova","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2026.118184_b0235","doi-asserted-by":"crossref","first-page":"257","DOI":"10.20517\/cdr.2022.136","article-title":"Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects","volume":"6","author":"Gmeiner","year":"2023","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0240","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s10020-022-00516-2","article-title":"MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy","volume":"28","author":"Matuszyk","year":"2022","journal-title":"Mol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0245","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s44276-024-00111-4","article-title":"Increased potentiation of 5-fluorouracil induced thymidylate synthase inhibition by 5,10-methylenetetrahydrofolate (arfolitixorin) compared to leucovorin in patients with colorectal liver metastases; The Modelle-001 Trial","volume":"2","author":"Taflin","year":"2024","journal-title":"BJC Rep"},{"issue":"5","key":"10.1016\/j.bcp.2026.118184_b0250","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41388-021-02121-9","article-title":"Thymidylate synthase O-GlcNAcylation: a molecular mechanism of 5-FU sensitization in colorectal cancer","volume":"41","author":"Very","year":"2022","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bcp.2026.118184_b0255","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3390\/biomedicines10061267","article-title":"Thymidylate Synthase Overexpression Drives the Invasive Phenotype in Colon Cancer Cells","volume":"10","author":"Ciszewski","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0260","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12885-025-13654-7","article-title":"Raltitrexed, S-1 and fruquintinib (RSF) in the treatment of refractory metastatic colorectal cancer: study protocol for a multicenter, prospective, single-arm, phase II trial","volume":"25","author":"Leng","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2026.118184_b0265","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1450418","article-title":"The role of l-leucovorin uptake and metabolism in the modulation of 5-fluorouracil efficacy and antifolate toxicity","volume":"15","author":"Peters","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118184_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102144","article-title":"Apigenin enhances apoptosis induction by 5-fluorouracil through regulation of thymidylate synthase in colorectal cancer cells","volume":"47","author":"Yang","year":"2021","journal-title":"Redox Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118184_b0275","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/carcin\/bgy186","article-title":"Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells","volume":"40","author":"Sakatani","year":"2019","journal-title":"Carcinogenesis"},{"issue":"12","key":"10.1016\/j.bcp.2026.118184_b0280","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.3390\/cancers14122928","article-title":"Drug Resistance in Colorectal Cancer: From Mechanism to Clinic","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"29","key":"10.1016\/j.bcp.2026.118184_b0285","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1038\/s41388-020-1352-y","article-title":"SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression","volume":"39","author":"Zhang","year":"2020","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.bcp.2026.118184_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116473","article-title":"PreTA-mediated metabolism of 5-fluorouracil by intratumoral Citrobacter freundii drives chemoresistance in pancreatic cancer","volume":"44","author":"Xu","year":"2025","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.bcp.2026.118184_b0295","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1021\/acsptsci.2c00117","article-title":"Dihydropyrimidine Dehydrogenase-Mediated Resistance to 5-Fluorouracil: Mechanistic Investigation and Solution","volume":"5","author":"Verma","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.118184_b0300","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41416-024-02754-z","article-title":"DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review","volume":"131","author":"Chan","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0305","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1021\/acs.jmedchem.1c01733","article-title":"A 5-FU Precursor Designed to Evade Anabolic and Catabolic Drug Pathways and Activated by Pd Chemistry In Vitro and In Vivo","volume":"65","author":"Adam","year":"2022","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2026.118184_b0310","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s10637-020-00930-5","article-title":"A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer","volume":"38","author":"Yamamoto","year":"2020","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bcp.2026.118184_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104717","article-title":"S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer","volume":"155","author":"Zhang","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0320","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13046-024-03010-1","article-title":"A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)","volume":"43","author":"Spiliopoulou","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0325","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2026.118184_b0330","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1042\/BCJ20180848","article-title":"Structural basis for the bypass of the major oxaliplatin-DNA adducts by human DNA polymerase \u03b7","volume":"476","author":"Ouzon-Shubeita","year":"2019","journal-title":"Biochem. J"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0335","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1186\/s12935-020-01668-z","article-title":"Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer","volume":"20","author":"Sun","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"12","key":"10.1016\/j.bcp.2026.118184_b0340","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/s41416-022-01742-5","article-title":"Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity","volume":"126","author":"Laoukili","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2026.118184_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111629","article-title":"Oxaliplatin disrupts nucleolar function through biophysical disintegration","volume":"41","author":"Schmidt","year":"2022","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.bcp.2026.118184_b0350","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1093\/nar\/gkae102","article-title":"Novel insights into the role of translesion synthesis polymerase in DNA incorporation and bypass of 5-fluorouracil in colorectal cancer","volume":"52","author":"Averill","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2026.118184_b0355","article-title":"PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway","volume":"9","author":"Li","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0360","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s42004-022-00661-z","article-title":"A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance","volume":"5","author":"Fronik","year":"2022","journal-title":"Commun Chem"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0365","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41419-025-07374-w","article-title":"Long noncoding RNA GDIL acts as a scaffold for CHAC1 and XRN2 to promote platinum resistance of colorectal cancer through inhibition of glutathione degradation","volume":"16","author":"Deng","year":"2025","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0370","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s42003-025-08584-w","article-title":"UBAP2L-driven stress granule formation links oxaliplatin resistance to gastric cancer","volume":"8","author":"Wu","year":"2025","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0375","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12885-016-3001-y","article-title":"Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer","volume":"17","author":"Palshof","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2026.118184_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108072","article-title":"TDP1 represents a promising therapeutic target for overcoming tumor resistance to chemotherapeutic agents: progress and potential","volume":"154","author":"Zhang","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2026.118184_b0385","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/15384047.2017.1414754","article-title":"Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer","volume":"19","author":"Shaojun","year":"2018","journal-title":"Cancer Biol. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2026.118184_b0390","first-page":"3890","article-title":"Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer","volume":"17","author":"Buck","year":"2019","journal-title":"Oncol Lett"},{"issue":"4","key":"10.1016\/j.bcp.2026.118184_b0395","first-page":"946","article-title":"Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review","volume":"4","author":"Ozawa","year":"2021","journal-title":"CancerDrug Resist"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0400","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.118184_b0405","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3390\/medicina61071202","article-title":"RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches","volume":"61","author":"S\u00fctc\u00fco\u011flu","year":"2025","journal-title":"Medicina (Kaunas)"},{"issue":"5","key":"10.1016\/j.bcp.2026.118184_b0410","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00432-013-1400-x","article-title":"PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis","volume":"139","author":"Wu","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118184_b0415","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/15384047.2020.1798695","article-title":"Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy","volume":"21","author":"Price","year":"2020","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0420","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1038\/s41467-025-59588-3","article-title":"Ligand-activated EGFR\/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer","volume":"16","author":"Qu","year":"2025","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bcp.2026.118184_b0425","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(25)00352-3","article-title":"Health-related quality of life in patients with KRAS(G12C)-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial","volume":"26","author":"Modest","year":"2025","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118184_b0430","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov."},{"issue":"8013","key":"10.1016\/j.bcp.2026.118184_b0435","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","article-title":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","volume":"629","author":"Holderfield","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118184_b0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116725","article-title":"PROTAC technology: From drug development to probe technology for target deconvolution","volume":"276","author":"Yan","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0445","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","article-title":"Discovery of KRAS(G12D) selective degrader ASP3082","volume":"8","author":"Yoshinari","year":"2025","journal-title":"Commun Chem"},{"issue":"8","key":"10.1016\/j.bcp.2026.118184_b0450","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted Degradation of Oncogenic KRAS(G12C) by VHL-Recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"6715","key":"10.1016\/j.bcp.2026.118184_b0455","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.bcp.2026.118184_b0460","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.3390\/cancers15245805","article-title":"The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer Cells","volume":"15","author":"Chapdelaine","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.bcp.2026.118184_b0465","doi-asserted-by":"crossref","first-page":"e694","DOI":"10.1002\/mco2.694","article-title":"Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies","volume":"5","author":"Ou","year":"2024","journal-title":"MedComm"},{"issue":"9","key":"10.1016\/j.bcp.2026.118184_b0470","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3390\/cancers17091493","article-title":"Targeting c-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications","volume":"17","author":"Ji","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2026.118184_b0475","article-title":"Prognostic and predictive molecular biomarkers in colorectal cancer","volume":"15","author":"Zhang","year":"2025","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118184_b0480","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/cancers10100342","article-title":"Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer","volume":"10","author":"Nami","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0485","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bcp.2026.118184_b0490","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3390\/medicina61091619","article-title":"The Receptor Tyrosine Kinase Axl in (Advanced) Gastric Cancer-From Pathophysiology to Therapeutic Impact","volume":"61","author":"Schreiner","year":"2025","journal-title":"Medicina (Kaunas)"},{"issue":"5","key":"10.1016\/j.bcp.2026.118184_b0495","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41419-019-1601-6","article-title":"AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells","volume":"10","author":"Kim","year":"2019","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bcp.2026.118184_b0500","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1541-7786.MCR-19-0956","article-title":"IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer","volume":"18","author":"Manabe","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0505","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1186\/s12885-025-14145-5","article-title":"MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis","volume":"25","author":"Hu","year":"2025","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.bcp.2026.118184_b0510","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-021-01553-w","article-title":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial","volume":"27","author":"Nakamura","year":"2021","journal-title":"Nat. Med."},{"issue":"50","key":"10.1016\/j.bcp.2026.118184_b0515","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.18632\/oncotarget.27114","article-title":"DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model","volume":"10","author":"Jimbo","year":"2019","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bcp.2026.118184_b0520","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3390\/ijms19041232","article-title":"Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway","volume":"19","author":"Itatani","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.118184_b0525","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/cancers17040663","article-title":"Real-World Evidence of Bevacizumab and Panitumumab Drug Resistance and Drug Ineffectiveness from EudraVigilance Database","volume":"17","author":"Vonica","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"17","key":"10.1016\/j.bcp.2026.118184_b0530","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.3390\/cancers16173103","article-title":"Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance","volume":"16","author":"Boichuk","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.bcp.2026.118184_b0535","first-page":"e1318","article-title":"Vascular co-option and vasculogenic mimicry mediate resistance to antiangiogenic strategies","volume":"5","author":"Pezzella","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"issue":"15","key":"10.1016\/j.bcp.2026.118184_b0540","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-24-0281","article-title":"FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer","volume":"30","author":"Fusco","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.bcp.2026.118184_b0545","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.3390\/molecules24162865","article-title":"Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model","volume":"24","author":"Mueller","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2026.118184_b0550","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1157596","article-title":"Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial","volume":"13","author":"Ferreira","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118184_b0555","article-title":"Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity","volume":"13","author":"Aristin Revilla","year":"2022","journal-title":"Metabolic Adaptation, and Therapeutic Targeting. Front Immunol"},{"issue":"11","key":"10.1016\/j.bcp.2026.118184_b0560","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s00262-020-02622-8","article-title":"Metabolomic profiling of tumor-infiltrating macrophages during tumor growth","volume":"69","author":"Umemura","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0565","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12916-023-02866-y","article-title":"Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability","volume":"21","author":"Wu","year":"2023","journal-title":"BMC Med."},{"issue":"11","key":"10.1016\/j.bcp.2026.118184_b0570","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013027","article-title":"Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8(+) T cells","volume":"13","author":"Chen","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2026.118184_b0575","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.bcp.2026.118184_b0580","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1158\/1541-7786.MCR-20-0308","article-title":"A TGF\u03b2-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair-Deficient\/Microsatellite Instability-High Colorectal Cancer","volume":"18","author":"Endo","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118184_b0585","doi-asserted-by":"crossref","DOI":"10.4161\/onci.29256","article-title":"Characterization of an adaptive immune response in microsatellite-instable colorectal cancer","volume":"3","author":"Boissi\u00e8re-Michot","year":"2014","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.bcp.2026.118184_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102618","article-title":"Sustained and specific multiplexed immune checkpoint modulation in CAR T cells induced by targeted epigenome editing","volume":"36","author":"Roman Azcona","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0595","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118184_b0600","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0605","doi-asserted-by":"crossref","first-page":"37515","DOI":"10.1038\/s41598-025-21400-z","article-title":"Novel anti-LAG-3 antibody LBL-007 with anti-PD-1 blockade enhances antitumor immunity by promoting T cell-induced apoptosis","volume":"15","author":"Qin","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0610","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s43556-025-00267-6","article-title":"TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives","volume":"6","author":"Yan","year":"2025","journal-title":"Mol Biomed"},{"key":"10.1016\/j.bcp.2026.118184_b0615","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658681","article-title":"Fusobacterium nucleatum Facilitates M2 Macrophage Polarization and Colorectal Carcinoma Progression by Activating TLR4\/NF-\u03baB\/S100A9 Cascade","volume":"12","author":"Hu","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118184_b0620","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jcmgh.2021.06.001","article-title":"Lactobacillus rhamnosus GG Orchestrates an Antitumor Immune Response","volume":"12","author":"Owens","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"6529","key":"10.1016\/j.bcp.2026.118184_b0625","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bcp.2026.118184_b0630","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1124\/pharmrev.123.000901","article-title":"Prostaglandin E2 in the Tumor Microenvironment, a Convoluted Affair Mediated by EP Receptors 2 and 4","volume":"76","author":"Santiso","year":"2024","journal-title":"Pharmacol. Rev."},{"issue":"11","key":"10.1016\/j.bcp.2026.118184_b0635","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00262-011-1064-9","article-title":"Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4","volume":"60","author":"Holt","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bcp.2026.118184_b0640","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1209572","article-title":"PGE2-EP2\/EP4 signaling elicits mesoCAR T cell immunosuppression in pancreatic cancer","volume":"14","author":"Akbari","year":"2023","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118184_b0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110914","article-title":"PGE(2)-EP2\/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment","volume":"39","author":"Thumkeo","year":"2022","journal-title":"Cell Rep."},{"issue":"28","key":"10.1016\/j.bcp.2026.118184_b0650","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.3748\/wjg.v27.i28.4653","article-title":"Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility","volume":"27","author":"Ji","year":"2021","journal-title":"World J. Gastroenterol."},{"issue":"24","key":"10.1016\/j.bcp.2026.118184_b0655","doi-asserted-by":"crossref","first-page":"12191","DOI":"10.3390\/ijms262412191","article-title":"The Role of Prostaglandins as Major Inflammatory Mediators in Colorectal Cancer","volume":"26","author":"Macia Guardado","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118184_b0660","doi-asserted-by":"crossref","first-page":"0304","DOI":"10.34133\/bmr.0304","article-title":"Cellulose Nanocrystal-Based Sulfatase-Responsive Hydrogel for Sustained Celecoxib Release in Ulcerative Colitis Therapy","volume":"30","author":"Pomseethong","year":"2026","journal-title":"Biomater Res"},{"issue":"5","key":"10.1016\/j.bcp.2026.118184_b0665","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/pharmaceutics13050731","article-title":"Ileo-Colon Targeting of the Poorly Water-Soluble Drug Celecoxib Using a pH-Dependent Coating in Combination with Self-Emulsifying Drug Delivery or Solid Dispersion Systems","volume":"13","author":"Broesder","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2026.118184_b0670","article-title":"Repurposing celecoxib for colorectal cancer targeting via pH-triggered ultra-elastic nanovesicles: Pronounced efficacy through up-regulation of Wnt\/\u03b2-catenin pathway in DMH-induced tumorigenesis","volume":"7","author":"El Menshawe","year":"2024","journal-title":"Int J Pharm X"},{"key":"10.1016\/j.bcp.2026.118184_b0675","article-title":"A self-delivery albumin nanomedicine amplified photodynamic therapy against esophageal cancer through COX-2\/PGE2 interruption and regulation of mitochondrial respiratory","volume":"10","author":"Xu","year":"2025","journal-title":"Int J Pharm X"},{"issue":"13","key":"10.1016\/j.bcp.2026.118184_b0680","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1021\/acs.inorgchem.5c05908","article-title":"Dual-Action NSAID-Gold(I) Alkynyl Hybrids for Synergistic Anti-Inflammatory and Anticancer Therapy of Colorectal Cancer","volume":"65","author":"S\u00e1ez","year":"2026","journal-title":"Inorg. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0685","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40164-025-00676-x","article-title":"Platelets in cancer and immunotherapy: functional dynamics and therapeutic opportunities","volume":"14","author":"Cai","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0690","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13402-025-01129-7","article-title":"Platelets in the tumor microenvironment: potential mediators of immune exclusion and resistance to immune checkpoint inhibitor therapy","volume":"49","author":"Nasir Kansestani","year":"2026","journal-title":"Cell. Oncol. (Dordr.)"},{"issue":"8060","key":"10.1016\/j.bcp.2026.118184_b0695","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41586-025-08626-7","article-title":"Aspirin prevents metastasis by limiting platelet TXA(2) suppression of T cell immunity","volume":"640","author":"Yang","year":"2025","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0700","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12964-025-02034-0","article-title":"PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer","volume":"23","author":"Li","year":"2025","journal-title":"Cell Commun. Signal"},{"issue":"5","key":"10.1016\/j.bcp.2026.118184_b0705","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/0008-5472.CAN-24-1611","article-title":"Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer","volume":"85","author":"Cui","year":"2025","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118184_b0710","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-17-1327","article-title":"Genetic Mechanisms of Immune Evasion in Colorectal Cancer","volume":"8","author":"Grasso","year":"2018","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0715","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/ijms24010118","article-title":"A Comprehensive Biomarker Analysis of Microsatellite Unstable\/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy","volume":"24","author":"\u00c9lez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2026.118184_b0720","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0725","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-017-0471-6","article-title":"Wnt\/beta-catenin pathway: modulating anticancer immune response","volume":"10","author":"Pai","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"13","key":"10.1016\/j.bcp.2026.118184_b0730","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1158\/1078-0432.CCR-21-0401","article-title":"A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H\/dMMR Gastrointestinal Tumors","volume":"27","author":"Chida","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118184_b0735","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study","volume":"40","author":"Lenz","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118184_b0740","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008689","article-title":"Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"12","author":"Overman","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118184_b0745","article-title":"Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118184_b0750","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211072703","article-title":"Precision medicine for metastatic colorectal cancer in clinical practice","volume":"14","author":"Riedesser","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.bcp.2026.118184_b0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107271","article-title":"Dual inhibitors of DNMT and HDAC remodels the immune microenvironment of colorectal cancer and enhances the efficacy of anti-PD-L1 therapy","volume":"206","author":"Yang","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0760","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40364-024-00640-7","article-title":"Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer","volume":"12","author":"Fan","year":"2024","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0765","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12964-023-01430-8","article-title":"New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses","volume":"22","author":"Kamrani","year":"2024","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0770","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40425-019-0575-3","article-title":"CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids","volume":"7","author":"Gonzalez-Exposito","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118184_b0775","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1016646","article-title":"Mechanism and strategies of immunotherapy resistance in colorectal cancer","volume":"13","author":"Shan","year":"2022","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118184_b0780","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0785","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-020-00430-1","article-title":"Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents","volume":"6","author":"Zhou","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2026.118184_b0790","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41419-024-06817-0","article-title":"Golgi dispersal in cancer stem cells promotes chemoresistance of colorectal cancer via the Golgi stress response","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.bcp.2026.118184_b0795","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/carcin\/bgv250","article-title":"Homeostatic responses of colonic LGR5+ stem cells following acute in vivo exposure to a genotoxic carcinogen","volume":"37","author":"Kim","year":"2016","journal-title":"Carcinogenesis"},{"issue":"6","key":"10.1016\/j.bcp.2026.118184_b0800","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/09553002.2019.1580401","article-title":"Radiation-induced DNA damage response and resistance in colorectal cancer stem-like cells","volume":"95","author":"Anuja","year":"2019","journal-title":"Int. J. Radiat Biol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118184_b0805","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3390\/cells9061392","article-title":"The Roles of Cancer Stem Cells and Therapy Resistance in Colorectal Carcinoma","volume":"9","author":"Das","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.bcp.2026.118184_b0810","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3390\/ijms26020664","article-title":"Energy Metabolism and Stemness and the Role of Lauric Acid in Reversing 5-Fluorouracil Resistance in Colorectal Cancer Cells","volume":"26","author":"Fujiwara-Tani","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.bcp.2026.118184_b0815","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.7150\/thno.44147","article-title":"Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer","volume":"10","author":"Liao","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2026.118184_b0820","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.692940","article-title":"Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers","volume":"9","author":"Lei","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"13","key":"10.1016\/j.bcp.2026.118184_b0825","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1084\/jem.20131195","article-title":"Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A","volume":"210","author":"Lotti","year":"2013","journal-title":"J. Exp. Med."},{"issue":"14","key":"10.1016\/j.bcp.2026.118184_b0830","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.7150\/thno.25541","article-title":"Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19","volume":"8","author":"Ren","year":"2018","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0835","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40164-024-00474-x","article-title":"Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs","volume":"13","author":"Zhao","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"Pt 3","key":"10.1016\/j.bcp.2026.118184_b0840","article-title":"Co-Colorectal cancer stem cells employ the FADS1\/DDA axis to evade NK cell-mediated immunosuppression after co-cultured with NK cells under hypoxia","volume":"143","author":"Geng","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0845","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13046-021-01934-6","article-title":"Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt\/\u03b2-catenin pathway","volume":"40","author":"Liu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118184_b0850","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3727\/096504016X14772331883976","article-title":"Overexpression of PER3 inhibits self-renewal capability and chemoresistance of colorectal cancer stem-like cells via inhibition of notch and \u03b2-catenin signaling","volume":"25","author":"Zhang","year":"2017","journal-title":"Oncol. Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.118184_b0855","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1002\/jcb.29473","article-title":"LncRNA-cCSC1 modulates cancer stem cell properties in colorectal cancer via activation of the Hedgehog signaling pathway","volume":"121","author":"Zhou","year":"2020","journal-title":"J. Cell. Biochem."},{"issue":"30","key":"10.1016\/j.bcp.2026.118184_b0860","doi-asserted-by":"crossref","first-page":"49807","DOI":"10.18632\/oncotarget.17971","article-title":"Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.bcp.2026.118184_b0865","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3390\/cancers14051281","article-title":"Metformin and ICG-001 act synergistically to abrogate cancer stem cells-mediated chemoresistance in colorectal cancer by promoting apoptosis and autophagy","volume":"14","author":"Roy","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0870","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41419-025-07902-8","article-title":"Valproic acid improves the efficacy of oxaliplatin\/fluoropyrimidine-based chemotherapy by targeting cancer stem cell via \u03b2-Catenin modulation in colorectal cancer","volume":"16","author":"Roca","year":"2025","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bcp.2026.118184_b0875","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3390\/ijms19041098","article-title":"Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture","volume":"19","author":"Usui","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118184_b0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118774","article-title":"Discovery of novel napabucasins bearing sulfonylpiperazine scaffolds as potent STAT3 inhibitors for the treatment of prostate cancer","volume":"309","author":"Zhang","year":"2026","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2026.118184_b0885","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1021\/acsptsci.1c00257","article-title":"Therapeutic Targeting of Cancer Stem Cells Prevents Resistance of Colorectal Cancer Cells to MEK Inhibition","volume":"5","author":"Lamichhane","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bcp.2026.118184_b0890","doi-asserted-by":"crossref","first-page":"879","DOI":"10.18632\/oncotarget.28517","article-title":"Inhibiting BRAF\/EGFR\/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells","volume":"14","author":"Lamichhane","year":"2023","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.bcp.2026.118184_b0895","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.3390\/cancers13163927","article-title":"Nobiletin and Xanthohumol Sensitize Colorectal Cancer Stem Cells to Standard Chemotherapy","volume":"13","author":"Turdo","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.bcp.2026.118184_b0900","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bcp.2026.118184_b0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106850","article-title":"Colorectal cancer stem cell vaccine with high expression of MUC1 serves as a novel prophylactic vaccine for colorectal cancer","volume":"88","author":"Guo","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2026.118184_b0910","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5680327","article-title":"A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma","volume":"2019","author":"Pang","year":"2019","journal-title":"Stem Cells Int."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0915","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3390\/ijms22010241","article-title":"ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models","volume":"22","author":"Yeom","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2026.118184_b0920","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3390\/pharmaceutics17091164","article-title":"Strategic and chemical advances in antibody-drug conjugates","volume":"17","author":"Alradwan","year":"2025","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.bcp.2026.118184_b0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188623","article-title":"Drug resistance in colorectal cancer: An epigenetic overview","volume":"1876","author":"Luo","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2026.118184_b0930","first-page":"838","article-title":"Epigenetic drivers of chemoresistance in nucleobase and nucleoside analog therapies","volume":"14","author":"Kaszycki","year":"2025","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.bcp.2026.118184_b0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101821","article-title":"Epigenetic modifications: key players in cancer heterogeneity and drug resistance","volume":"39","author":"Sadida","year":"2024","journal-title":"Transl. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118184_b0940","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41419-021-03734-4","article-title":"TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability","volume":"12","author":"Zhou","year":"2021","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.bcp.2026.118184_b0945","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.3390\/cancers15082222","article-title":"The emerging role of histone deacetylase inhibitors in cervical cancer therapy","volume":"15","author":"Psilopatis","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0950","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12935-025-03992-8","article-title":"Epigenetic potentiation of 5-fluorouracil by HDAC inhibitor quisinostat enhances antitumor effects in colorectal cancer","volume":"25","author":"Calibasi-Kocal","year":"2025","journal-title":"Cancer Cell Int."},{"issue":"51","key":"10.1016\/j.bcp.2026.118184_b0955","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb8626","article-title":"The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment","volume":"6","author":"Juh\u00e1sz","year":"2020","journal-title":"Sci. Adv."},{"issue":"13","key":"10.1016\/j.bcp.2026.118184_b0960","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1158\/1078-0432.CCR-18-3769","article-title":"miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial","volume":"25","author":"Anandappa","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118184_b0965","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/ijc.32608","article-title":"Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells","volume":"146","author":"Deng","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118184_b0970","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8421614","article-title":"Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells","volume":"2017","author":"Xiong","year":"2017","journal-title":"Biomed Res. Int."},{"issue":"7","key":"10.1016\/j.bcp.2026.118184_b0975","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18197","article-title":"Competitive endogenous RNA networks: Decoding the role of long non-coding RNAs and circular RNAs in colorectal cancer chemoresistance","volume":"28","author":"Khalafizadeh","year":"2024","journal-title":"J. Cell Mol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0980","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1186\/s12935-021-02353-5","article-title":"Long noncoding RNA CRART16 confers 5-FU resistance in colorectal cancer cells by sponging miR-193b-5p","volume":"21","author":"Wang","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2026.118184_b0985","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12935-020-1155-9","article-title":"The novel long noncoding RNA CRART16 confers cetuximab resistance in colorectal cancer cells by enhancing ERBB3 expression via miR-371a-5p","volume":"20","author":"Zhang","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"3","key":"10.1016\/j.bcp.2026.118184_b0990","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/1878-0261.12629","article-title":"Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer","volume":"14","author":"Wang","year":"2020","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b0995","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2026.118184_b1000","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/1878-0261.12965","article-title":"The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer","volume":"15","author":"Sreekumar","year":"2021","journal-title":"Mol. Oncol."},{"issue":"22","key":"10.1016\/j.bcp.2026.118184_b1005","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.3390\/nu15224705","article-title":"The Role of Cyanidin-3-O-glucoside in Modulating Oxaliplatin Resistance by Reversing Mesenchymal Phenotype in Colorectal Cancer","volume":"15","author":"Kurter","year":"2023","journal-title":"Nutrients"},{"issue":"14","key":"10.1016\/j.bcp.2026.118184_b1010","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.7150\/jca.19142","article-title":"HES1 Promotes Colorectal Cancer Cell Resistance To 5-Fu by Inducing Of EMT and ABC Transporter Proteins","volume":"8","author":"Sun","year":"2017","journal-title":"J. Cancer"},{"issue":"559","key":"10.1016\/j.bcp.2026.118184_b1015","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz4589","article-title":"A YAP\/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components","volume":"12","author":"Nilsson","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118184_b1020","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41388-018-0454-2","article-title":"Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI","volume":"38","author":"Weng","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b1025","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1038\/s41467-018-05992-x","article-title":"EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"issue":"7693","key":"10.1016\/j.bcp.2026.118184_b1030","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bcp.2026.118184_b1035","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.trecan.2020.02.001","article-title":"Tumor Plasticity and Resistance to Immunotherapy","volume":"6","author":"Horn","year":"2020","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.118184_b1040","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1271858","article-title":"Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity","volume":"6","author":"Terry","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bcp.2026.118184_b1045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.897927","article-title":"Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy","volume":"12","author":"Schiffmann","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118184_b1050","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1310397","article-title":"Doxorubicin-sensitive and -resistant colorectal cancer spheroid models: assessing tumor microenvironment features for therapeutic modulation","volume":"11","author":"Valente","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b1055","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41416-018-0198-3","article-title":"Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer","volume":"120","author":"Schiffmann","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118184_b1060","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.808859","article-title":"Tumor-Derived Lactate Creates a Favorable Niche for Tumor via Supplying Energy Source for Tumor and Modulating the Tumor Microenvironment","volume":"10","author":"Jin","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118184_b1065","first-page":"938","article-title":"Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance","volume":"55","author":"Yue","year":"2023","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b1070","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/jcp.26917","article-title":"New strategies for targeting glucose metabolism-mediated acidosis for colorectal cancer therapy","volume":"234","author":"Wang","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b1075","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1038\/s41598-025-33862-2","article-title":"The significance of immunogenic cell death related prognostic gene markers in colorectal cancer prognosis and antitumor immunity","volume":"16","author":"Dong","year":"2026","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.bcp.2026.118184_b1080","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113270","article-title":"Collagen 1-mediated CXCL1 secretion in tumor cells activates fibroblasts to promote radioresistance of esophageal cancer","volume":"42","author":"Yang","year":"2023","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.bcp.2026.118184_b1085","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/bjc.2017.13","article-title":"A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition","volume":"116","author":"Schiffmann","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b1090","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s10020-021-00402-3","article-title":"Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis","volume":"27","author":"Chen","year":"2021","journal-title":"Mol. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118184_b1095","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/cpt.3528","article-title":"Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib\/II MORPHEUS Trial","volume":"117","author":"Ko","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2026.118184_b1100","first-page":"126","article-title":"CRCs-CAFs crosstalk-targeted nano-delivery system reprograms tumor microenvironment for oxaliplatin resistance reversing and liver metastasis inhibition in colorectal cancer","volume":"54","author":"Liu","year":"2025","journal-title":"Bioact. Mater."},{"issue":"9","key":"10.1016\/j.bcp.2026.118184_b1105","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","article-title":"Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers","volume":"25","author":"Parikh","year":"2019","journal-title":"Nat. Med."},{"issue":"24","key":"10.1016\/j.bcp.2026.118184_b1110","doi-asserted-by":"crossref","first-page":"11127","DOI":"10.7150\/thno.47448","article-title":"Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin","volume":"10","author":"Vaidya","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b1115","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13046-023-02853-4","article-title":"Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer","volume":"42","author":"Cartry","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b1120","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12943-024-02180-y","article-title":"THBS2\u2009+\u2009cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K\/AKT activation in colorectal cancer","volume":"23","author":"Zhou","year":"2024","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2026.118184_b1125","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.3390\/ijms21093166","article-title":"Convolutional Neural Network Can Recognize Drug Resistance of Single Cancer Cells","volume":"21","author":"Yanagisawa","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b1130","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1038\/s41467-024-47957-3","article-title":"Network-based elucidation of colon cancer drug resistance mechanisms by phosphoproteomic time-series analysis","volume":"15","author":"Rosenberger","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118184_b1135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-022-01241-3","article-title":"BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers","volume":"15","author":"Khan","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.118184_b1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217821","article-title":"Role of artificial intelligence in cancer drug discovery and development","volume":"627","author":"Sarvepalli","year":"2025","journal-title":"Cancer Lett."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600523X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600523X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:57:03Z","timestamp":1785902223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522600523X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":228,"alternative-id":["S000629522600523X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118184","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidimensional regulatory networks of drug resistance in colorectal cancer: from molecular mechanisms to novel therapeutic counterstrategies","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118184"}}